Chariw registraiion number.. 1198095 Cotnpanv registrdtion number.. CE028473 AMMF - The Cholangiocarcinoma Charity (A Charitable Incorporated Organisation} Annual Report and Financial Staiements for ihe Year End￿ 31 January ?025 Edtnund c￿ LLP Chartered Accountants & Statut(Trry Auditor 146 New" London Road Chelmsford CM* OAW AMMF- The Cholangiocarcinoma Charity Contents Reference and Administrative Dethils Trustees, Report 2to 13 Statemeni of TrUs￿e5, Res￿nSIbIlitieS 14 Independent Auditoes ReEKTrrt 15to 19 Statement of Financial Activities Bplanc¢ Sh¢¢¢ 21 Stat¢rn¢nl of Cash Flows 22 Notes (o the Financial Sthiemenis ?3to33 AMMF- The Cholangiocarcinoma Charity Referenee and Administratii'e Details Chairman Mr Noel Corrigan Tru5tee5 Mrs Gillian Corrigan Mr Harold Corrigan Mr Torn Morement Senior Man3gernent l Leadership Mrs Helen Moremeni. CEO Ttam Registered Office Eni¢rprise House BossingtrM)um Road Siansied CM*4 IQW The charily is incorporated in England and Wales. 1198095 Charity RtRlStrAiion Number Company Registration Number CE028473 Auditor Edmund ca￿ LLP Chartered Aecounianis & Staiuiory Auditor 146 Ne*" l.ondon Road Chelmsford CMI OAW Page I AMMF- THE CHOLANGIOCARCINOMA CHARIT IREGISTERED NO: 11980951 REPORT OF THE TRUSTEES FOR THE YEAR ENDEO 31 JANUARY 2025 NOTE FROM THETRUSTEES: AMMF- The Cholanglocarclnoma Charlty was reglstered wlth the Charlty Commlsslon as Charltable Incorporatèd Organisatlon ICIOI durlnÈ ihe year 2022. The CIO re8lstered number wlth the Charity Commission is 1198095. The charity was originally registered in 2￿2 under the name. The Alan Morement Memorial Fund (working title. AMMFI and was an unincorporated charity with the registration number 1091915. However, because of the continuin8 growth of the charity. AMMF'S trustees decided that it should transltion as a legal entity from unincorporated re8lStered charity status to that of a Charitable Incorporated Organi5ation ICIOI. This involved lengthy work with the Charity Commi55ion, and the new CIO 5tatU5 was approved on 01 June, 2022. At that point the work and all a55ets of the original charity passed to the new CIO charity. The original charity and its registered number 1091915 will always remain in existence, with all records submitted to the Charlty Commission still available on the Commission's website, but thls entity will now remain in the background. The new CIO Is offl¢lally known as". AMMF- The Cholan8locardnoma Charlty. wlth the re8lstered number: 1198095. AMMF 's alms and obje￿ve5 remaln unchanged and the charws work has contlnued seamlessly and wlthout Interruptlon slnce the In¢eptk)n of the CIO *)n 01 June 2022. Page 2 AMMF- The Cholangiocarcinoma Charity Trustees. Report The trustees present their report with the financial statements of the charity for the year ended 31 January 2025. The trustees have adopted the provision5 of Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard 3pplicable in the UK and Republic of Ireland IFRS 1021 (effective l January 20191. OBJECTIVES AND ACTIVITIES Oblectlves and alms AMMF s MISSION A world improvedfor the cholongiocorcinomo ptstient by the shoring of knowledge across the heolthcore ond research communities and with theAomily of oAfected people across the globe. AMMF'S VISION A world where people con live their liveslree of cholongio¢or¢inomo ICCAJ os o life-threotening disease. AMMF- the Cholangiocarclnoma Charity Is the only charity in the UK solely dedicated to cholan8iocarcinoma Ibile duci cancer). AMMF works nationally throughout the UK, as well as In Europe, and collaborates globally. AMMF is wholly committed nationally and internationally to tackling the devastating primary liver cancer, cholangiocarcinoma ICCAI on all fronts an(l. ultimately, to help find a cure, through.. Support- Providin8 information to individuals or groups to support a patient or loved one along their journey Empowerrnent- Empowering Patients and their loved ones to advocate for themselves, seek better care. new treatment options and second opinions A¢cess- Advocating for patients to ensure they have access to the latest treatment options antl a minimum standard of care appropriate to them Awareness- Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches Research- Encouraging and supporting continued research into causes. diagnostics, and new treatment options for those with cholangiocarcinoma Policy- Working toward5 ensuring health care policies reflert the need5 of those with cholangiocarcinoma Page 3 AMMF- The Cholangiocarcinoma Charity Trustees. Report Cholan8iocarcinoma is under-represente(l and under-funded across all areas, including policy. services, and re5e3Tch. It 15 a Poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accuratedia8no515, mean that most are at an advanced stage and inoperable at time of their diagnosis. Whilst surgery remains the only potentially curative treatment, there is now chemotherapy, targeted therapies and immunotherapy. and a growing number of clinical trials. in particular those investigating further targeted therapies and immunotherapies. However, a diagnosis of inoperable cholanBiocarcinoma remains invariably fatal, and this is a situation that has not chan8ed in decades. AMMF is committed to working to change this scenario, nationally and internationally. Resolute In bringinB about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients anil their carers, clinicians, healthcare professionals, researchers, and pollcy makers, as well as actively collaboratin8 8lobally. During the year 2024, the charity continued its advocacy work, especially in helping those with cholan8lOC3rcinoma to navigate their way to continue essential treatments wherever possible. Ralsbn8 Awareness The Rethlnk Ll¥er Cancer Canyl8n The alm of AMMF'S 'Rethink Liver Cancerf campai8n Is to broaden the focus of liver cancer from being exclusively hepatocellular carcinoma IHCCI to hi8hli8ht that cholan8iocarcinoma ICC41 is also a primary liver cancer, and to raise awareness and influence health policy for better reco8nition, earlier diagnosi5, and equitable treatment access. 'S0ft launched, in October 2023 ILiver Cancer Awarene55 Monthl. The Rethink Liver Cancer Campaign, was formally launched on 20 February 2024 with a White Paperl based on the outcomes and the publications from AMMF'S CCA data work. at an afternoon tea reception in The Terrace Pavillion at the House of Commons. Westminster. AMMWS Westmlnster Receptlon- February 2024 Elliot Colburn MP, Chair of the All Party Parliamentary Group on Cancer, hosted the event and met and spoke with many of the guests. Noel Corrigan, Chair of AMMF'S Trustees, introduced the formal part of the afternoon, Elliot Colburn gave an introdvrtorytalk, and AMMF'S new video showcasing the finding5 of the CCA data project was premiered. Helen Morement, AMMF'5 CEO, and Professor Shahid Khan of Imperial College London. then spoke about what led to the CCA data project, the results and the asks we now have for those who can change policy and improve the situation for all those with CCA. Page 4 AMMF- The Cholangiocarcinoma Charity Trustees. Report Amongst the attendees were a number of health care professionals with an interest in CCA, MPS and government health officials, NHS policy makers, patients and carers, and mernbers of the press. AMMF'S Westminster reception reSU￿ed in press coverage of the event and the White Paper in some 140 different media outlets, nationally and intern3tionally. mmf. hink-liv r-whi htt outube.com watchkn8C2nlz3-bc8&t=25s AMMF'S Hybrld European Cholanglocarclnoma Conlefence- May 2024 AMMF'S European Cholangiocarcinom3 Conference 2024 was a three-day hybrid event showcaslng groundbreakin8 research, innovative treatments, and the collaborative spirit of the cholangiocarcinoma ICCAI community. The charity was delighted to welcome two internationally renowned specialists at the forefront of the CCA world, Professor Shahid Khan and Professor Chiara 8raconi, as co-chairs of the 2024 Conference. They expertly hosted a faculty of 45 intemational speakers and managed some challenging Q & A sessions. all exploring the conference theme- Accelerating Progress. As in prevlous years, the conference brought together a diverse audience, Includlng healthcare professionals IHCPSI, researchers, medicèl students, patient organisations, patients, carers and patient advocates. Thi5 mix provided a unique platfomi for exchanging knowledge and perspectives, enhancing the understanding and management of CCA. Impattful personal perspectives were shared by four CCA patients. Their powerful individual stories highlighted real-world challenges including the crucial need for specialist knowledge, early diagnosls, and comprehensive support systems. AMMF'S conference was endorsed by the Bri f h Liver and wasaCPD accredited event. worth 22.5 hours CPD (Continuing Professional Development). The full programme and all conference presenlatiorbs from the three days were recorded and remain available to view via AMMF's web51te. See- htt amml.or .uk ammf-conlerence-2024 AMMF Cllnlcal Nurse Speclallst Advlsory Board- May 2024 On 08 May 2024. during AMMF'S CCA conference. a workshop for ainical Nurse Specialists ICNSI was held. Following this, at the nurses, request. an AMMF CNS Advisory Board has been set up. CNS Advisory Board Terms of Reference were prepared, circulated and approved, and a virtual meeting of the board will be scheduled for early in 2025. Page 5 AMMF- The Cholangiocarcinoma Charity Trustees. Report Faces of Cholang5ocarclnoma- December 2024 The 'Faces of Cholangiocarcinom3' initiative was part of the next stage of the Rethink Liver Cancer campaign, which it Is planned will run throughout 2025. To promote the ask for a 'Fairer Deal, Fasterf for all those with cholangiocarcinoma, a photo shoot was arranged with the celebrity photographer. Rankin IRankin waived his fee for the day. although the charity had to pay for the studio and ancillary personnel). Eight people with cholan8iocarcinoma were photographed, including the designer Dame Zandra Rhodes, Katie Nichol (author and roy31 commentorl, Charlie Shrager Imodell, and others well known to AMMF - Ilona Smith, Andrea Sheardown, Andy Clav, Judith Neptial, 8enjamin Carev. As part of this venture, a'behind the scenes. video was created, which will be launched at the start of February 2025, Cholangiocarcinoma Awareness Month= ww. And a new campaign video, "Rethink Liver Cancer- for a Fairer Deal Fastert for 2025 has been created, using interviews and film captured during the day at Rankin's studio- htt www. tub orm wa loCFcubu Global Cholon8lo¢ar¢lnoma Alllance The Global Cholangiocarcinoma Alliance IGCAI was established at AMMF'S international workshop held in London in 2018. The aim of the Alliance 15 to provide a united voice through international collaboration, raise the global awareness of CCA, and to improve the education of both healthcare professlonals and patients. Since the GCA'S inception in 2018, AMMF has acted 3$ the not-for-profit partner in this venture, and AMMF'S CEO Helen Morement is a co-chair on the international steering committee. Durlng 2024 the role of secretariat of the GCA, and the organisation of the annual World Cholangiocarcinoma Day in February, cholan8iocarcinom3 Awareness Month, passed from the healthcare communications agenry AXON to Colab Health who will now also manage the bespoke website and social media accounts. Publlc Benefft In forming the tharitvs objettives and pl3nning the activitie5. the trustee5 have considered the Charity Commi55ion'$ 8uidance in respect of public benefit. ACHlEVEmEP￿ AND PERFORMANCE AMMF'S Researth Awards Page 6 AMMF- The Cholangiocarcinoma Charity Trustees. Report AMMF remains committed to supporting research into cholangiotarcinoma. In 2024, based on the advice of AMMF'5 Scientific Advisory Board awards were offered and accepted by the following to support their research into cholangiocarcinoma.. Unlverslty ol BlmilnRharn (Mr Kayanl Kay•nll- AMMF Ref: 20241224 'Stable funttional induced tre8s'. A novel means of immunosuppression for patients transplanted for cholangiocarcinoma in the era of transplant oncology" Award: £99.557.81 (to be given in one instalmentl Unlverslty College London HospStal lor Uma Mukherleel- AMMF Ref: 20241225 "Identifying and predictin8 resistante mutations in intrahepatic cholangiocarcinoma liCC41" Award: £17.331.73 (to be given in two instalmentsl Imperlal College London (Prof Shahld Khan)- AMMF Ret: 20241226 'Multiplexed detection of cell-free DNA, microRNA, and protein biomarkers to diagnose Cholangiocarcinoma and Hepatocellular Carcinoma using a novel nanopore-based sensing technolog Award: £45,000.IX) (to be given in two instalmentsl Durlng 2024 the followlng payments were made re exlstlng awards: Unlverslty of Nottln8ham- AMMF Ref: 20221214 An award iotalling £24,250.00 was agreed to fund consumables in the work of Professor Kevin Gaston, Professor Sheela Jèyarèman and DT Isioma Egbuniwe on, "Ultra high- resolution mapping of spatial patterns of 8ene and protein expression in cholan8iocarcinoma and the cholangiocarcinoma tumour microemiironment~. The following payments Itotalling £24.010.051 were made in respect of invol￿S received, for consumables used: £5.472.00 was paid on 07.03.2024 £2,226.67 was paid on 29.05.2024 £2,226.67 was paid on 14.06.2024 £14.084.71 was paid on 23.12.2024 Unlverslty of Glasgow- AMMF ref: 20231218 £49,732.00 was p3id on 18.03.24 representing the first inst3lment of the award of £99,464.00 agreed to fund the work of Professor Chiara Braconi and Dr Jen Morton in, 'Identifying therapeutic opportunities for Biliary Cancers by investigating the role of Monocytes in drug response~. Page 7 AMMF- The Cholangiocarcinoma Charity Trustees. Report Imperfal College London- AMMF Ref: 20241226 £22.500.00 was paid on 23.12.24 representing the first instalment of the award of £24.WO.00 agreed to fund the work of Professor Shahid Khan in, "Multiplexed detection of cell-free DNA. microRNA. and protein biomarkers to diagnose Cholangiocarcinoma and Hepatocellular Carcinoma using a novel nanopore-based sensing technology-. AMMF'S Extemal Actlvltles The charity is recognized widely, nationally and internationally, amonBSt both the general public and within medical circles, for its work in the field of cholangioc3rcinoma. and is frequently invited to become part of study groups and advisory boards. for example, the working group for Liver Transplantation for Cholangiocarcinoma, and the executive committee of Cholangiocarcinoma-UK. AMMF is a150 a member of the European Network for the Study of Cholangiocarcinoma IENS-CCAI, an association of research groups from across Europe and beyond, actively working on basic. translational, and clinical research into cholangiocarcinoma. and AMMF'S CEO is chair of the ENS. CCA Patient Advocacy Committee. AMMF continues to be an active member of Cancer52. the alliance of rare and less common cancer organisations in the UK. AMMF'S CEO, Helen Morement was appointed a board dirertor/trustee of Cancer52 in 2014, and has continue(J in that role since then. She also ècted as interim co-chair during 2023 and part of 2024 Iwith fellow Cancer52 board member, Rebetca Porta, CEO of The Urologv Foundation) until the new Chair of Trustees was appointed. Through membership of Cancer52, AMMF is enabled to have a presence and a voice within every national cancer initiative and AMMF'S trustees see this as providing an important opportunity to work more closely with this influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common caneers community. BSG18ritish Society for Gastroenterolowil Guldellnes for the Olagnosls and Mana8ement of CholanRiocar¢inoma Led by Profe550r Shahid Khan. Imperial College London, and oriBinally published in 2023, the guidelines which had been prepared by a multidisciplinary writing committee of UK experts from various specialties involved in the diagnosis and management of CCA. including AMMF'S CEO. were updated during 2024 to include information on molecular profilin& targeted therapies, and the follow-up protocol after surgical resection for cholangiocarcinoma. AMMF'S CEO, Helen Morement. also had discussions with David Fitzgerald. Director- Policy and Strategy, NHS Cancer Programme, NHS England, who agreed that the guidelines, along with a data analysis of the various CCA therapies given, c3ncer 3lli3nce by cancer alliance lextratted from AMMF'S published data workl, should be circulated to all cancer alliance5 in England. This was done in October 2024. Page 8 AMMF- The Cholangiocarcinoma Charity Trustees, Report For more inAormtstion and the BSG guidelines. see.- h ond-manu ement-o iocorcinoma uidelines- or-the-diu nO$￿- HP8 Pathway to Olagnosls During the year, AMMF'S CEO worked with Peter Hawkins. Pro8ramme Manager for Faster Diagnosi5, NHS Cancer Prograrnme, NHS England, on the HPB (Hepatobiliaryl Cancer5 Diagn05tic Pathways document. This document is to be used by all cancer alliances, their respective NHS trusts and other stakeholders. See.. htt land.nhs.uk ublication Im lementin -a-tlmed-h b- Cancer-dia n05Lic- athwa ancreatic-liver-bile-duct-and all-bladder New therapy appralsal5: NICE INatlonal Ins￿tute lor Care and Excellence) and SMC {Scottlsh Medldnes Consortluml Durlng 2024, AMMF was Invited to submit written and oral statements in support of new therapy appraisals by NICE and the SMC. Followin8 submissions and full appraisals, the following new therapies for cholangiocarcinoma were approved during 2024: By NICE.. Futibatinib ILytgobil- for those with a previously treated advanced cholanglocarclnoma wlth FGFR2 fusion or rearrangement. By theSMC: Ivosidenib ITib50voI'. a 2nd line treatment for those with an IDHI mutation. External events As the charlty contlnues to expand Its work throughout the UK and into Europe, during the year AMMF'S CEO received a number of invitations to speak about cholangiocarcinoma and the work of the charity at national and international conference5 during the year and presented at the following: 02 February- CCA-UK ICholangiocarcinoma-UKI: Annual Meetingi London. 08 February- ILCM Ilnternational Liver Cancer Movement) CCA Webinar Ivirtuall. 15 February- APIC Iltalian CC4 Patients Association) Annual rneeting Ivirtuall. 26-27 April - ILCA Ilnternational Liver Cancer Associationl Congress, Madrid, Spain. Page 9 AMMF- The Cholangiocarcinoma Charity Trustees, Report 01-02 July- ENS-CCA IEuropean Network for the Stu(ty of Cholangiocarcinomal Conference, Krakow. Poland. 19 July- NHS En8land- Circulating DNA ICtONAI and Genomics Conference. London. 13- 17 September, ESMO (European Society of Medical Oncology) Annual Congress and ATUVIBI (Spanish CCA advocacy group) event, Barcelona, Spain. 30 September- UnSvers1ty of Glasgow & Universlty of Edinburgh. NHS Scotland- Scottish Perspective on Biliary Cancers- Ounblane, Scotland. Other external events: 01- 06 June- ASCO 2024. AMMF'S CEO Helen Morement and trustee Gilllan Corrlgan attended this internationally renowned annual oncology event in Chica80, USA. This provided an opportunity for meeting with and fostering new pharmaceutical industry relationships, and with international CCA specialists and other patient advocacy 8roups. They also attended the A8C-07 trial outcome presentation and, as the CEO was a member of the trial management group headed by Professor Maria Hawkins, who is a member of AMMF'S Clinical and Medical Advi50ry Board, it was considered important for AMMF to have a presence at this everrt. 10 Ortober.. Nottingham Nurses, Event- two members ofAMMF's team (Natasha Plte and Julie Cross) attended the event to 5howca5e the work of the charity and the resources the charity has for both nurses and patients. AMMF'S CEO Awarded an Honorary Dortorate On 17 July 2024, Helen Morement, the founder and Chief Executive of AMMF-The Cholanglocarclnoma Charity was awarded the honorary degree of Doctor of Sclence honor15 causo In a graduation ceremony at the University of Nottingham in recognition of her Service to medicine and science over more than two decades. Helen was nominated for this prestigious degree by Professor Kevin Gaston. Professor of Cancer Science5, Faculty of Medicine and Health Sciences at the University of Nottingham. The award recognises her outstanding contribution through the work of AMMF. in the field of cholan8iocarcinoma. Page 10 AMMF- The Cholangiocarcinoma Charity Trustees. Report Professor David Bates, Professor of Ontology and Director of the University of Nottingham's Centre for Cancer Sciences. delivered an Oration in which he OLrtlined Helen's work explaining that, as a consequence of this work. development of and access to clinical trials. surgery, information and drug therapies have improved, and that she continues to advoc3te for a more widespread approach fo¥ fair and equitable treatment. Providing information for those who need It AMMF'S CEO attended the virtual NHS cancer charity briefing meetings throughout 2024. These regular meetings have proved helpful and informative. providin@ details of new developments in NHS processes and policies in a timely manner. AMMF'S Medical and Clinical Advisors are contacted on a regular basis for help and advice on how best to handle the more difficult patient queries the charity receive5, and for up to date inforniation on clinical trials. AMMF'S webslte contlnued to be updated regularly, and provldes information on all asperts of cholangiocarcinoma, including treotments and specialists, the advances being made and, importantly, there 15 a comprehensive list of the clinical trials that are available and recruiting in the UK, which is provin8 a valuable resource to healthcare professionals and patients. www. mmf. The charity uses a number of social media platfomis- Facebook, X Iformerly Twitter), Insta8ram, Linkedln. These are each kept up to date with daily information of importance and relevance to supporters. The number of follower5 on each continues to grow. with Facebook in particular now at over 6,300 followers. AMMF'S three private, member only, support groups on Faceb¢x*k, Cholangiocartinoma Support- UK and Europe.. for Patients and CaTeTs, for Patients Only, and for those bereaved, continue to grow, The groups provide an invaluable resource for patients and their loved ones and, moderated by three knowledgeable voltjnteers, each group is a safe and private space in which to Sha￿ information, and to help and support each other. The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to grow. Page 11 AMMF- The Cholangiocarcinoma Charity Trustees. Report As we look to 2025 ... The Rethink Liver Can¢er Campaign •nd Westminster Reception 2025 The Rethink Liver Cancer campaign is ongoing and will continue into 2025, especially during Februarvs Cholangiocarcinoma Awareness Month when we will be holding a further reception in Westminster, in the House of Commons Churchill Room. The event will be hosted by Mary Glindon, MP for Newcastle upon Tyne East & Wallsend. We hope those who took part in the Faces of Cholan8iocarcinoma event in December 2024 will atten(l. to add strength to the charity's ask of those with the power to change policy for a'fairer deal fasterf for all those diagnosed with cholangiocarcinoma. Centres of CCA Expertlse The outtomes of the CCA data projert and the publication of the new BSG Guidelines for the Diagn0515 and Management of CCA gave AMMF the ammunition to begin work towards building the case for Centres of CCA Expertise. During 2024. a working group of specialists in CCA has joined with AMMF in this work, and in planning a hospital audit to ascertain the numbers of those diagnosed with CCA and the treatments they attually receive. AMMF'S Hybrld European Cholanglocarclnoma Conference 2025 The 2025 conference will take place 07- 09 May with 3 global faculty and co-chairs, Dr Helnz-josef Klumpen and Ms Rachel Gvest, two internationally renowned specialists at the forefront of the CCA world. And Flnallv AMMF ha$ 8rown steadily over the years and, with the continued help of loyal funtlraisers and supporters, sponsor and advisors, we will continue our work and remain fully committed to working towards a fèr better future for all those diagnosed with cholan8i¢xarcinoma. At the heart of everythin8 we do is the cholangiocarcinoma patient and their families, and each and every day all of us at AMMF strive towards that improved future for all those diagnosed with this most challenging of cancers. AMMF will continue it5 work until that goal is reached. Flnanclal revlew Financial rèview and reseNes pollcy The charity ha5 continued to strengthen its financial position during the year. The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations. Where specific research projects have been secured. the trustees designate sufficient unrestricted reserves to cover the experted future grants payable over the term of the research projert. Page 12 AMMF- The Cholangiocarcinoma Charity Trustees. Report Note IS to the financial statements details the movement on restricted and unrestricted funds during the accounting period. Of total fund5, £1,112,245 15 freely available betause the balance has a restriction for other purp05e5. Restricted funds totalled £147.539 and total fund5 for the period were £1,259.784. STRucfuRE, GOVERNANCE AND MANAGEMENT Governlng document The charity is controlled by its governing document, a deed of trust, and constitutes an incorporated charitv. Approved by order of the board of trustees on . 25 Novemtw 2025 and signed on its behalf bv.. Noel Corrigan- Chair of Trustee5 Page 13 AMMF- The Cholangiocarcinoma Charity Statement of Trustees, Responsibilities The trnstees {￿'hO are also the directors of AMMF - The Cholangiocarcinoina Charity for the purposes of ompany law) are responsible for preparing the Trustees, Report and the financial staterneJ)Is in accordance with applicable law and United Kingdom Accounting Stsndards {United Kingdorn Generdlly Accepted Accoujiting Practice). including FRS 10? "The Financial Reporting Standard applicabl¢ in the UK and R¢publi¢ of Ireland" The repon and accounts have been prepared in accordance M'ith th¢ provisioiis in the Companies Act 2006 relating to Small companies. Company law requires ihe tnjstees io prepare financial sthiemenis (01 each financial year. Under company la Ihe trustees must noi approve ihe financial sthiemenis unless ihev are saii5fied ihai the) give a irue and fair view of ihe stale of affairs of ihe charithble companv and of ihe incoming resources and application of resources, including lis income and expenditure, of ihe Chari￿bIe company for ihai period. In preparing ihege financial staiemenis, the trustees are required io.. select suitable accounting policies and apply them Consis￿ni1y- observ¢ the methods and principles in ihe Charities SORP: make judgements and eslima￿S ihai are reasonable and prndeni: state whether applicable accoun¢ing siandards. comprising FRS 10? have been follo￿¢d, subject to any material departures disclosed and explained in the finwicial siaiements: and prepare the financial siaiemenis on the going ¢one¢m basis unless it is inappropriate to presume that ihe charitable eompany w'ill continue in business. The trustees are responsible for keeping proper accounting records (hai can disclose ￿1th reasonable accuracy at any time the financial position of the charitable company and enable them 10 ensure Ihat ihe financial staiemenis comply with ihe Companies Aci fj006. "lThey are also reswnsible for safegiuarding the assets of ihe charitable company and hence for taking reasonable steps for ihe preveniion and deiection of fraud and o(her I￿egular1tjes. Page 14 AMMF- The Cholangiocarcinoma Charity Independent Auditor's Report to the Members of AMMF - The Cholangioeareinoma Charity Opinion We have audited ihe financial sthtements of AMMF - The Cholangiocarcinoma Charity (the 'chariry') for the year ended 31 January )O?S. which comprise the Sthtement of Financial Activities. Balance Sheet. Statemeni of Cash Flo￿.$. and Noies to the Financial Sthiemenis. including significani accounring w)licies. The financial reporting frdmework thai has been applied in iheir prepardiion is applicable la￿ and United Kingdom Accounting Siandards. including Financial Reponing Sthndard 10? The Financial Reporting Standard applicable in the IIK and Republic of Ireland (Uniied Kingdom Generdllv AcceP￿d Accouniing Practice). In our opinion th¢ financial 5tatemenls'. give a true and fair view, of the siaie of the charilv's atrairs as ai 31 January ?0?5 and of its incoming resources and application of resources. including its income and expendiiure. for rhe vear then ended: have been properly prepared in accordance M'ith Unl￿d Kingdom Gencrally Accepicd Accouiiiii)L Practice., have been prepa￿d in a¢¢ordan¢¢ with the r¢quir¢ments of the Compani¢s A¢1 ?006. Basis for opinion We condiicted our audil in a¢¢ordan¢e with Internalional Stondards on Audiling IUK) {ISAs (UK)) and applicabl¢ law. Our r¢sponsibiliti¢s under ihos¢ siAndards ar¢ furth¢r d¢scribed in tli¢ auditor r¢sponsibilili¢s for the aiidii ofihe finartcial staiemenis seciion of our report. We are independeni of the charity in accordai)ee with the Lthical reqiiiremenis thai are relevani io our audii of ihe financial stsiements in the UK. includii)b ihe FRC'S Ethical Standard. and we httve fulfilled our oiher eihical responsibilities in accordance with tl)ese requireiMei)ts. We bcli¢v¢ that th¢ aLidii ¢viden¢e M¢ hav¢ obtain¢d is sU￿1¢l¢nI and appropriate to provide a basis for our opinion. ComparAtifve peiod The finaniial siatements for the year ended 31 January ?0?4 M'ere subject to an independent examination and not an aiidii. Accordinglj.. the comparative infom)aiion presenied does noi include an auditor's opinitsn. Page 15 AMMF- The Cholangiocarcinoma Charity Independent Auditor's Report to the Members of AMMF - The Cholangioeareinoma Charity CoNclllsioN% relating to goiThg CODcerD We have nothing to repon in respect of the following mallers in relation to which the ISAS {UKI require us to report to you ￿here'. th¢ trnst¢¢s' us¢ of the going ¢on¢¢rn basis of xcounling tn the preparntion of the financial STat¢m¢nts is not appropriate., or the trustees have noi disclosed in ihe financial stsiements any identified material uncertainties thai may casi significani doubt about the charity s abilit>, io coniinue io adopt the going concern basis of aceouniing for a period of at leasi twelve months from the dale w.hen ihe financial sthiements ale authorised for issue. Conelusions relating to going eoneern In auditin¥ ihe ljnanLial siatemenls, M'e have cimcluded that ihe tnjsiees, use of the going concern basis of accoun(in¥ in the preparation of the financial siaiernenis is appropriaie. Based on the work we have perfomied. we have noi ideniified any maierial uncertainties relaiing to evenis or condiiions that, individually or colleciiwely. may casi significani doubl on ihe charity's abilily 10 coI)iinue as a goiiig> concern for a period of ai leasi iwelve months from M'hen the financial sthtements are auihorised for issue. Our responsibiliiies and the Tesponsibililies of the Iwslees M'ith respeci to bJoin¥y concern are descTibed in the relevant section5 of this report. Other informatlon 'I'he oiher inf()nnaiion comprises ihe informalion included in the annual report. other ihan the finai)cial stat¢rn¢nis and our audilor s report thereon. The tTUSi¢¢S are reswnsible for the other infomia¢ion coiiiained ithin the annual Teport. Our opinion on the financial Stalemen￿ does not cover ihe oiher infonnation and, except lo ihe extent otherwise explicitly siaied in our report. we do not express anj forni of assurance conclusion thereon. Our re5ponsibili¢y is to read th¢ other informaliiTrn and. in doing so. consider Hh¢ther the other inforniation is mat¢riallv inconsis¢en¢ w'ith the financial statements or our knowledge obtsiiied in ihe course of ihe audit or oth¢rwise appears to be mai¢riallv mi&51at¢d. If *'e identify such ma¢erial in¢(TriisiSt¢ncie5 or apparenl material misstatements, w'e ar¢ ￿qUIred io delerniine w'heih¢r ihis gives rise lo a ma¢erial miss¢alemenl in ¢he finaiicial statemenis ¢h¢mselves. If, bas¢d on th¢ w'ork. w'e have perfo￿¢￿. we conclude thal there is a material misstatement of this other infornla¢ii￿, Me are required to report that fad. We have nothing to rew)rt in thL5 regard. Page 16 AMMF- The Cholangiocarcinoma Charity Independent Auditor's Report to the Members of AMMF - The Cholangioeareinoma Charity Opinion on other matters prescribed by the CompaThies Act 21M16 In our opinion. based on the ￿'OrK. undertaken in ihe course of ihe audit.. th¢ infomiation given in th¢ Trnstees, Rew)rt lincorpordting the Direciors, Report) for th¢ fijiancial y¢ar for which th¢ financial stai¢m¢nts are pr¢par¢d is consistent M'ith th¢ financial statements: w)d the Directors. Report has been prepared in accordance M'ith applicable legal requirements. Matters on which we are required to report by exception We have noihing to report in iespeci of the follow'ing mailers in relation ￿ which the Charities (Accounts and Reports) Re¥ulaiions ?008 require us io report 10 you if. in our opinion.. the infomiation givcn in the financial siatcmenLS is inconsisieni in any material respect with the trustees, report; or the charitabl¢ company has noi kept adequate accounting records: or the financial siaiemenis are noi in agreemeni with ihe aecouniing records and rdurns: or 'c havc not rcceivcd all ihe infomialion and explanaiions we require for our audii. Responsibilities oftru5tces As LxplainLd more fLIII J irt the Staiemeni of Trusitts. Responsibilities lsd out on page 141. Ihe trustees (who are also (he directors of ihe charity for ihe pUr￿e$ of company law) are responsible for ihe preparaiion of the rinancial siaiemenis and for beinb? satisfied thai they bjive a true and fair view. and for such ii)iernal control as the trustees detcrmine is necessary to enable ihe preparation or rinancial ststements thai are frcc froin material misstatement, whether due io fraud or error. In preparing) the financial slaiemenis. the iTusiees are responsible for assessing) the charity's ability to continue as a going) concern, disclosing. as applicable. mailers related io going concern and using the going? coiicem basis of accounting unless the ¢rus¢ees either inlend io liquidate ihe charity or to cease operd¢ions. or have no realistic altemative bu¢ io do so. Auditor responsibilities for the audit of the finaneial si#temtnts We have been appointed as auditor uJideT Section 144 of the Charities Act ?01 l and report in accordance with Tegulations made under section 154 of thai Acl. Our objeciives are to obtain Teasonoble assurance aboul M'hether the financial staiernents as a whole are free from material misstatement, whether due to fraud or error. and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurAnce, but is not a guaranree thai an audit conducted in accordance with ISAS {UKI M'ill always detect a material rnisstatement M,h¢n it ¢XLSt%. Mi%stat¢m¢nts ¢an arise from fraud or error and are coiisidered material if. individuallv or in the aggregate. they could reasonably be ¢xp¢ct¢d to influence the e¢onomi¢ d¢cisions of users taken on the basis of th¢s¢ financial statements. Irregularitie5, including fraud. are instances of not￿O[￿p]iance w'ith laivs and regulations. We design procedures in line w'ith our rcswn5ibilitie5, outlined a￿Ve. to detect material mi55tatement5 in respect of irre¥uldrities. includin¥ fraud. The extent to ￿'hiCh our procedure5 are capable of detecting irre¥ularities, including fraud 15 detailed below: Page 17 AMMF- The Cholangiocarcinoma Charity Independent Auditor's Report to the Members of AMMF - The Cholangioeareinoma Charity Irregularities, including fraud. are instances of notKompliance M'ith laivs and regulatioiis. We design procedures in line with our resEx)nsibiliiies, outlined above. to delect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and th¢ ¢xt¢nt to ￿'hich thes¢ ar¢ capabl¢ of d¢t¢¢tingJ irr¢gulariti¢s, including fraud is d¢tail¢d b¢10￿.: Our hi fonvard Total funds carried fonvard 954.799 80.596 1.035.39S 965.870 17 1.11? ?45 147.539 1 ?59.784 1,035.395 All of the charity's ac¢ivilies derive from continuing operations during the above Iwo periods. AMMF- The Cholangiocarcinoma Charity (Registration number: CE028473) (Chariti. number: 1198095) Balanee Sheet as at 31 Januan 2025 (As restated) 2024 2025 Note Fixed assets Tangible assets 10 7,783 4,219 Current assets Stocks Debtors Cash ai bank and in hand 9.839 6.635 69.633 1.14?.07? 12 13 l.J94.776 1,489.902 ,218.340 Creditors: Amounts falling du¢ within one year 14 187.164 Net current assels ?5?.001 Net assets 1 ?59.784 1,035.395 Fund5 of the ch4rily: R￿tricted income funds Restricted lunds 17 147.539 80.596 Unrc5tricted income funds UnrLblriLlcd I'unds 9%4.799 Total funds 17 1 ?59.784 1.035.395 -I'he financial statements on pages 20 10 33 were approved by the trustees, and authorised for issue on 25 November 2025 . and si¥ned on their behalf by.. Mr Noel Corrigan Chaiman AMMF- The Cholangiocarcinoma Charity Statement of Cash Flows for the Year Ellded 31 January 2025 (A5 restated) 2024 2025 Note Cash flows from operaling activities Net movement in funds per SOFA 224.i89 69.525 Adju51m¢ntS Depr¢¢iation Invesiment income i.432 119.9291 111.854 ?07,89? 60,??? Working capital adjustrnent$ Ilncrcascl..'dccrca%e in stocks Increase in debiors Increase in creditors Inerek)se in deferred income (3.204) (15.6541 5.737 ?.s.000 751 (?9,4??1 127.776 12 14 Nei eash nows from operating activities ? J9.771 159.3?7 Cash flows from in%'¢5¢ing 8cliiilies Inli'r¢s1 r¢¢¢ivabli' ynd siinilar incom¢ Purchase of iangible fixed assets 19.929 6.996 11.854 155 10 Net cash flows from investing activities 11.699 Net increase in cash and cash equivalents ?52.704 171.0?6 Cash and cash equivalents ai l Febn 1.14•.07? 971.046 Cash and cash equivalents ai 31 January 1.394.776 1.14?.07? All of the cash flows are derived from continuing operations during the alx)ve two periods. AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 Aeetsunting policies Stalernent of compliance The accounts (financial sta￿Ments) have been prepared in acC(￿dance with the gthtement of Recommended Practice." Accouniing and Reporting by Charilies preparing iheir accounts in accordance w'ith ihe Financial Reponing Srandard applicable in the UK and Republic of Ireland IFRS 10?) issued on 16 July ?014 and the Financial Reporting Sthndard applicable in ihe Uniied Kingdom and Republic of Ireland (FRS 10?) and the Chariiies Aci 201 l and UK Generally AcCep￿d Practice as it applies from l January 2019. The accounts (financial siaiementsl have been prepared to give a'inje and fairf view and have depaned from the Chariiies (Accounis and RepLlrts) Regulaiions ?008 only io ihe extent required io provide a true and fair view,. 'I'his departure has involvcd follo￿Ing Accouniing and Rcportiiig bv Chariiics preparing rheir accouiiis in accordance M'iih ihe Financial Rcponing Standard applicablc in the IJK and Rcpublic of Ireland IFRS I O issucd on 16 July 1014 raihcr ihan ihc Accouniing and Rcponing by Chariiies.. Staieinent of Rccoinmcnded Practice effective from l April ?005 which has since been M'ithdrawn. Basis of preparatio AMMTr I'hL C-holan&Fiocarcinoma Chariry meeis the definiiion of a public benefii eniity under FRS 10? Assets and liabilities are initially Tecogynised at hislorical cosl or trdnsaciion value unless otheNise staled in the relevanl accountin& policy notes. Goin% eothtern The irusiees consider ihai ihere are no maierial uncenainiies about the chariiy's ability to coniinue as a kioing concern nor any significant areas of uncertainly thai affeci the carrying value ofassets held by the charily. Ineome and endowments All income is recognised once the charitv has enliilement to the income, it is probable that the income will be received and the amounl ofthe income receivable can be measured reliably. DoMoliou.% 4nd lexa¢ie5 Donation5 ar¢ re¢ognised w'hen the charity has been notified in writing of both lh¢ amount and settlement date. In thc cvcnt that a donation 15 subject to conditions that rcquire a levcl of ￿rfO￿lanCe bv thc charit* bcfoTC thc charitv 15 Clltitled to thc funds, the income 15 defcrred ￿ld not rccogniscd until cithcr those conditioiis arc fully met. or the fulfilttlent of th05c conditlOll5 is M holly H"ithin thc control of the charity and it Is probablc that thcsc conditions will be fulfillcd in the rcporting pcriod. DeAerred Incom Deferred income represenis amounts received for fuiure periods and is released io incoming resources in the period for which, it has been received. Such income is onlv deferred when= - The donor specifies that ihe grdni or donaiion musi only be used in fuiure accounting periiMAs.' or The donor has imposed conditions which must be before the charity has unconditional entitlement. Inv￿￿lent income Dividends are recognised once the dividend ha5 declared and notification has ￿ell received of the dividend due. AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 Expenditure All expendiiure is recognised once there is a legal or consiNctive obligation io thai expenditure, it is probable selllement is required and ihe amount can be measured reliablj.. All costs are allocated to the applicable expendiiiire heading ihai aggregaie similar costs io thai caiegory. Where costs cannoi be direcily atiribuied to panicular headings ihe}' have been allocated on a basis Consis￿￿1 ￿'1th the use of resources. wilh central staff cosis allocated on the basis of lime spenL and depreciaiion charges allocated on the portion of the asset's use. Other support costs are allocaied based on ihe spread of sthff costs. RalJingfund5 These are costs incurred in attracting volunlary incom¢. th¢ mynag¢tn¢nl of inv¢stm¢nt5 Jnd ihos¢ incurr¢d in tradin¥ Rctivities that rdiS¢ fund5. Churlluble ueilvilles Chariiable expenditure comprises those cosis incurred by the charity in the delivery of its activities and services for its beneficiaries. It ineludes boih costs ihai can be allocaied directly io such aciiyiiies and those costs of an indirect nature necessary io support them. Governance ¢oslS ThcsL include the cosis aiiribuiable io thc charity's compliance uiih consiiiuiional and sratuiory requirements, includinbi audit. siraieg>ic manas>emeni and uusiees mcciings and reimbursed cxpei)scs. Tangible fjxed a55et5 Individual filed assets costinb £50.00 or more are initially recorded ai cosi. less any subsequent accumulated deprecidti(Trn and subsequent accumulated impaimieni losses. Depreciation artd #mortisatio Depre¥iation is provided on ianbpible fixed assets so as 10 M'riie oif the cost or valuaiion. less any estimated residual value. over iheir expecied useful economic life as follows.. Asset class Computer equipment Deprecia¢ion method rate 33°. Stock Stock 15 valued ai the lower of cosi and estimated selling price less costs to complete and sell. after due re&Tard for obsolete and slow moving stocks. Cost is determined using the fi￿l-ln. fLl¥t-out IFIFOI. Trade debtors Trade debtor5 are amounts due from cu5tom¢r5 for merchandL5e 501d or services perfomed in the ordinary course of bu5ine55. Trade debtors are recognised initially ai ihe Irdnsaciion price. They are gubsequently measured ai amonised cost using the effective inierest method. less provision for impainnent. A provision for the impairnient of trade debtors is established w.hen there is objeciiye evidence ihai the chariiy m.ill noi be able io colleei all amounts due according (o the original tem)s of Ihe receivables. AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 Cash and cash equivalent5 C&sh and cash equivalents comprise cash on hand and call deposits. and other short-ierni highly liquid invesiments ihai are readily convenible to a known amouni of cash and are subject to an insignificant risk of chatige in value. Trade creditor5 Trade crediiors are obligarions io pay for giKKls or services ihai have been acquired in the ordinary course of business from suppliers. Accounis payable are classified as curreni liabiliiies if ihe charity does nL)t have an unconditional righi, ai thc end of thc rcwTrrting period, to dcfcr scrtlcmcnt of the crediior for ar least twelve months aftcr the rcponing daic. If thcrc is an uiicondiiional righi io defer settlemeni for at least twelve months after ihe reporting daic, they arc prcscnicd as noJKurrcni liabiliries. Tradc crcdiior% arc rccogniscd initially at the Irdnsaciion price and subsequently measured at amortised cost usingi the cffcctivc inicrest meihod. Fund structure Unrestricted income fund5 are general funds ihat are available for use at the tNslees's discretion in furtherance of the objeciives of the charily. Res¢ricl¢d income funds ar¢ those don¥ied for use in ¥ particular area or for SF¢¢ific purposes. the use of which is resiricied to that area or purpose. Financial instruments Financial assets and financial liabilili¢s are re¢ognised m.hen the tharity becom¢s a party to ih¢ eontractual provisions ofthe instrument. rinancial liabilitie5 and eqiiiiy instruments are classified according io the substance of the contractual arrangements entered into. An equity insimment is any conirdci that evidences a residual interest in the a55e(5 of the charity after deductin8 all of its liabilities. 2 Income from dona¢ion5 and leg4cie5 Unrestricted fund5 Restricted fund5 Tot#1 fund5 t)onation5 and legaci¢s 756.689 ?6? 781 1.019.470 Tolal for 2025 756.689 ?6* 781 1,019.470 (As restated) Total for 2024 699.595 228.)36 997.531 3 Income from other trading activities AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 Unrestricted funds Restricted funds Total funds Trading income; Shop income 6.4?? 6,422 Total for 2025 6.4?? 6,4?? Total for 2024 1?.470 12.470 4 Investment income Unr¢51ricied fynds Total funds Interest receivable and similar income. Inicrcst receivable on bank deposits Total for 2028 19.9?9 19.9?9 Total for 2024 11.854 11.854 5 Expenditure on charitable ac¢iii¢i¢$ (As restated) Total 2024 Unresiricied funds Total 2025 Restrleied Note ELiropcan Conference Costs 274.114 90,771 30?.638 576.75? 90,771 514.849 ?34 ?48 Granl5 ¢0 instilu¢ion5 European Website costs 9.58? Depreciation. amortisaiion and other similar costs StatTcosts Governance costs 3.432 133.689 14.085 133.689 14.085 109.782 5,347 516.091 30*.638 818.7?9 876.359 AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 6 Analysis of Eovernanee and support eosts Governance costs Total 2025 Total 2024 Audii fees Audit ofthe financial 51atem¢nts Ind¢p¢ndent ¢xamin¢r f¢¢5 Accounts and independent examinalion Payroll fees Bookeeping fees 1?.600 3.900 878 569 284 14.085 5.347 7 Net incomingloutgoing resourc¢$ Nei incomin&> resources for ihe year include.. 2025 2024 Audit fees Depreciation of fixed assets 12.600 3.43? ?.551 8 Tru5tee5 remuneration and expenses DurinbT the year Ihe charily made Ihe folloth'ing trdnsactions with trustees.. Mr Harold Corrigan £890 {?0?4.. £6161 ofexFenses were reimbursed to Mr Harold co￿lgan during the year. Mr Noel Corrigan £7671?U74.. I?051 of exFenses were reimbur5¢d to Mr Noel Corrigan during the year. Mr Tom Morement £479 {?024'. £Nil) of expenses were reimbursed io Mr Tom Morement durin¥ the year. Mrs Gilli#n Corrigan £2,048 (?074.. £Nil) of ex￿￿$£5 were reimbursed to Mrs Gillian co￿Lgan during the year. 9 Staff costs The aggregate payroll costs were as follows: AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 2025 2024 Staffeosts during the year were: Wages and salaries S(Kial security costs Pension costs 123,528 7.796 ?.365 104.451 3.776 1,555 133.689 109.782 The monthly average number of persons (including senior managem¢nt I l¢adership team) employed by the charity during ihe year expressed b! head couni was as follows-. 2025 No 2024 No Employees No employee received emoluments of more ihan £60.000 during the year. Th¢ to¢al employee benefits of the key management personvel of the charity were £52.463. 10 Tangible fixed assets Cornputer equipment Total Cost Ai l February ?024 Additions Disposals 13.135 6.996 3.fi8? 13.135 6.996 3.68? Ai 31 January 20?5 10.449 16.449 Depreciation At l February ?0?4 Charge for ihe year Eliminaied on dis￿saI$ 8.916 3.43? 3.68? 8.916 At 31 January ?025 8.666 8.666 r4et book value At 31 January 2025 7.783 7,783 At 31 January 2024 4,?19 4,219 I I Stock 2025 2024 Stock5 9.839 6.635 AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 12 Debtors (Ag reslated) 2024 2025 Trade debiors Prepayments Ac¢ru¢d incom¢ 18.800 46.?31 69.633 13 Cash and eash equivalents 2025 2024 Cash on hand Cash ai bank ?02 1.394.574 2S 1.14?.047 1,394.776 1,14•.07? 14 Creditors: amounts falling due within one year (As restated) 2024 2025 Trade creditors Accruals for &>ranis Other taxation and ￿CIal security Ac¢rLia15 Deferred income 13.394 168.938 3.94$ 76.6?4 ?.s.o(Jo 8.816 168.937 1,077 8,334 ?37.901 187.164 Resources deferred in the period •5.000 Included within dcferred income 15 £25.0￿ for swffl50r5hip for the ?025 AMMF Conference. 15 Obligations under leases and hire purchase contra£ts The total value of future minimum le&se pa>Tncnts was &s follows.. AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 2025 2024 Within one year In two to five years In over five years 19.425 4,770 12.360 47.655 37.080 16 Contingent liabilities At 31 January ?0?5 gyrdnts of £161.999 (?0?4.. £101.645) had awarded for which condiiions for the ogynition in the year had noi been met. 17 Funds Current Jwr.. Balance at I February 2024 Balanee at 31 January Res0￿ree9 txptnded resourees Transfers Urtrt.%lrlciédlund5 Gelleral l.Lind 954.799 783.040 (518.794) (106.800) 19,245 Restricted Res¢ric¢ed Research Funds European Websiie Project European Conference 2024 Lxtemal Projects ?1.120 93.606 32.938 97.848 5.000 140.963 105.000 {758) ?47.7(?3) 54.117 106.800 35.870 86.753 Total re51ri£led 80.596 ?6?.781 130?.6j8 106.800 147.539 Total fund5 1,035.395 1.045.8?1 1821,43? 1,2$9.784 Prlor}pe4r.' (As restated) Balancc at 31 January 2024 Balance at February 2023 lThcoming resources Resources expended Transfers Unre5trieted fundg Unreslrlciedfurtd Gen¢ral Funds 876,1?4 723.919 (613,321) (31,923) 954.799 Page 30 AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 (As restated) Balance at JI January 2024 Balance at I February 2023 Incoming resources Resources expended Transfers Restricted Restricted Research Funds European Websiie Project European Conference ?0?3 External Proj¢cts 33.6?6 35.(M)O {10,o?o) (191.8461 167.44)) 3.606 124.9?3 IOi.i13 31.923 35.870 Total restricted funds 89.746 ??8.? j6 1269.3091 31.9?3 80.596 Total funds 965.870 952.155 1887.630) 1,035.395 The specifie purposes for whi¢h th¢ funds are io be applied are as follows: Restrieied research funds represent donations m.here the donor has requesied th8t their donaiion be used for research purposes only. These donations are h¢ld M'iihiTr r¢strict¢d funds until utilised in part or in w,hole to fund a cholan￿10¢0r¢lnOma ￿$¢ar¢h proje¢1 w'hich lh¢ ¢harity has committed to support. Restrieied funds for each of the major projecis AMMF undettskes represeni those donations or sponsorships where the donor has requestcd ihai iheir monies be used for that particular projeci only. Those funds are held as resiricied fLinds until used in full or in part io complete the projeci for which thcy were byiven. Restrieied funds for the major. exiemal projecis AMMF uiidertakes represent sponsorships to support only those indiN idual 5pccific projccts for which the fundinb has bccn b¥iven. 'lThc nuinbcr of such projccts varics froim year io year. The transfer of £106,800 represents restricted projects and events funded from unrestricted fuiids due to a shortfall in furtdin8 received. 18 Analysis of net assets betwetn funds Total fund5 8t 31 J8nu8ry Unrestricted funds R¢stri¢ted funds 2025 Tangible fixed assels Curreni asseis Current liabilities 7.783 1.34?.363 ?j7.901 7,783 1,489.90? 12i7.901) 147.539 Total net assets 147.539 1 ?59.784 Page31 AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statements for the Year Ended 31 January 2025 (As restated) Total funds at 31 January 2024 Unreslrieled funds Restricted Tangible fjxed assets c￿￿ent assets Current liabilities 4,219 ,137.744 187,164 4,219 ,218,340 187 164 80,596 Totoi n¢t &ss¢ts 954.799 80,596 ,035.395 19 Related party transactions There wer¢ no r¢lated party transactions in the year. 20 Prior period adjustment Resiatetnent of prior period balances h&s tsken pla¢e, the 4djustsnents were made due to under provided a¢cured incorne and a¢rruais in the Year Ended 31 January 20?4. As a ￿￿11, in the comptytiv¢ figures, donations artd legaci¢s irtcom¢ and a¢cTued in¢ome hove in¢re4sed by £23.402 and Charl￿ble a¢iivÈiy expenditure and ac¢ruai$ have incr¢￿ed by £4,434. Also, the prior year ¢oniingeni liabiliiy was also understated. The ¢(*nparaiive irt no* 16 has been restated and incre&4ed by £14.325. This no affect on the prior veaws sutplus or balance sheet. Pag¢ 32 AMMF- The Cholangiocarcinoma Charity Notes to the Financial Statemellts for the Year Ended 31 January 2025 The following page does not fonn part of the statutory financial statements. Page 33 AMMF- The Cholangiocarcinoma Charity Detailed Statement of Financial Aetivities for the Year Ended 31 January 2025 Total 2025 Total 2024 Incorne and Endowm¢Dts from: Donations and legacies Other trading activities Investment incom 1,019.470 6.422 19.9?9 927.831 12.470 11,854 Total incotn¢ 1.045.8?1 95? 1.$5 Expenditure on: Raisin￿ funds Charitable activities (2,7031 {818.7?91 (6,2711 1876.3$91 Total expenditure {8?1,43 188?.6301 Net income ??4.389 Net movemeni in funds ?24.389 69.525 Reconciliation of funds Total funds brought fonvard l.Q35.395 965.870 Toial funds carried fonvard 1 ?59.784 1.035.395 This pag¢ does not forni part of the stslutory financial sratements. Page 34